PMVP — PMV Pharmaceuticals Balance Sheet
0.000.00%
- $74.19m
- -$68.09m
- 29
- 51
- 48
- 37
Annual balance sheet for PMV Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 361 | 297 | 241 | 203 | 169 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 365 | 301 | 247 | 207 | 176 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.569 | 13.2 | 20.5 | 19 | 1.55 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 366 | 332 | 270 | 252 | 191 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 6.41 | 12.2 | 10.8 | 14 | 14.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.41 | 23 | 24.3 | 26.5 | 15.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 359 | 309 | 246 | 226 | 176 |
| Total Liabilities & Shareholders' Equity | 366 | 332 | 270 | 252 | 191 |
| Total Common Shares Outstanding |